Tharimmune signs nonbinding LOI to merge with Intract Pharma; 49% stake for Intract shareholders

Canton Strategic Holdings, Inc.

Tharimmune and Intract Pharma entered nonbinding LOI; Tharimmune to acquire Intract for restricted stock.
Intract shareholders will own 49% of combined entity; merger expected to close in Q1 2025.
Combined company will leverage Intract's Soteria and Phloral oral delivery platforms for biologics.
Existing license for oral anti-TNF antibody (INT-023/TH023) from Intract remains unaffected.
Transaction aims to expand Tharimmune's pipeline in inflammation and immunology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.